RESEARCH PAPER
Raised concentrations of lipid peroxidation products (LPO) in pregnant women with impaired glucose tolerance
 
More details
Hide details
1
Department of Endocrinology and Metabolic Diseases, Medical University of Lodz, Lodz, Poland
2
Department of Endocrinology and Metabolic Diseases, Polish Mother’s Memorial Hospital – Research Institute, Lodz, Poland
3
Department of Diabetes and Endocrinology, Royal Free Hospital, Hampstead, London, UK
4
Department of Obstetrics and Gynaecology, Royal Free Hospital, Hampstead, London, UK
5
Department of Oncological Endocrinology, Medical University of Lodz, Lodz, Poland
 
Ann Agric Environ Med. 2014;21(2):429–434
KEYWORDS
ABSTRACT
Introduction:
Lipid peroxidation (LPO) results from oxidative damage to membrane lipids. Whereas LPO rises in normal pregnancy, the effect of gestational diabetes mellitus (GDM) on this process has not been clearly defined.

Material and Methods:
Fasting blood concentrations of malondialdehyde+4-hydroxyalkenals (MDA+4-HDA), as LPO index, TNFa soluble receptors (sTNF-R1 and sTNF-R2), and soluble adhesion molecules (sICAM-1, sVCAM-1), were measured in 51 women at 28 weeks of gestation. The women were divided according to the results of 50.0 g glucose challenge test (GCT) and 75.0 g oral glucose tolerance test (OGTT): Controls (n=20), normal responses to both GCT and OGTT; Intermediate Group (IG) (n=15), abnormal GCT but normal OGTT; GDM group (n=16), abnormal both GCT and OGTT.

Results:
Glucose concentrations in women diagnosed with GDM were within the range of impaired glucose tolerance. There were no significant differences in concentrations of either TNF a soluble receptors R1 and R2, or sICAM-1 or sVCAM-1. LPO concentrations [MDA+4-HDA (nmol/mg protein)] were significantly higher in women with GDM than in the other two groups [64.1±24.3 (mean±SD), 39.3±23.1, 47.0±18.1, for GDM, IG and Controls, respectively; p<0.05]. In multivariate analysis, the only significant independent correlation was between LPO level and glucose at 120 minutes of OGTT (rs=0.42; p=0.009).

Conclusions:
Oxidative damage to membrane lipids is increased in GDM and might result directly from hyperglycaemia. Physiological significance of this phenomenon remains to be elucidated.

 
REFERENCES (43)
1.
Voulgaridou GP, Anestopoulos I, Franco R, Panayiotidis MI, Pappa A. DNA damage induced by endogenous aldehydes: Current state of knowledge. Mutat Res. 2011; 711: 13–27.
 
2.
Dreher D, Junod AF. Role of oxygen free radicals in cancer development. Eur J Cancer. 1996; 32A: 30–38.
 
3.
Dröge W. Free radicals in the physiological control of cell function. Physiol Rev. 2002; 82: 47–95.
 
4.
Öztürk LK, Aykuz A, Yarat A, Koc S, Gul N, Dogan BN. Salivary lipid peroxidation and total sialic acid levels during healthy gestation and postpartum: A longitudinal sudy. Clin Biochem. 2010; 43: 430–434.
 
5.
Little RE, Gladen BC Levels of lipid peroxides in uncomplicated pregnancy: a review of literature. Reprod Toxicol. 1999; 13: 347–352.
 
6.
Weiss PA, Haeusler M, Kainer F, Purstner P, Hass J. Toward universal criteria for gestational diabetes: relationships between seventy-five and one hundred gram glucose loads and between capillary and venous glucose concentrations. Am J Obstet Gynecol. 1998; 178: 830–835.
 
7.
Faas MM, Moes H, de Vos P. Monocyte cytokine production during pregnancy. J Leucoc Biol. 2004; 75: 153–154.
 
8.
Guentsch A, Preshaw PM, Bremer-Streck S, Klinger G, Glockmann E, Sigush BW. Lipid peroxidation and antioxidant activity in saliva of periodontontitis patients: effect of smoking and periodontal treatment. Clin Oral Invest. 2008; 12: 345–352.
 
9.
Paradisi G, Biaggi A, Ferrazzani S, De Carolis S, Caruso A, Abnormal carbohydrate metabolism during pregnancy. Association with endothelial dysfunction Diabetes Care 2002; 25: 560–564.
 
10.
Wolf M, Sauk J, Shah A, Smirnakis KV, Jimenez-Kimble R, Ecker JL et al. Inflammation and glucose intolerance. A prospective study of gestational diabetes mellitus. Diabetes Care 2004; 27: 21–27.
 
11.
Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab. 2004; 89: 2548–2556.
 
12.
Fernández-Real JM, Straczkowski M, Lainez B, Chacón MR, Kowalska I, López-Bermejo A, et al. An alternative spliced variant of circulating soluble tumor necrosis factor-alpha receptor-2 is paradoxically associated with insulin action. Eur J Endocrinol. 2006; 154: 723–730.
 
13.
Safranow K, Dziedziejko V, Rzeuski R, Czyzycka E, Wojtarowicz A, Bińczak-Kuleta A, et al. Plasma concentrations of TNF-alpha and its soluble receptors sTNFR1 and sTNFR2 in patients with coronary artery disease. Tissue Antigens 2009; 74: 386–392.
 
14.
Nophar Y, Kemper O, Brakebusch C, Englemann H, Zwang R, Aderka D, et al. Soluble forms of tumor necrosis factors (TNF-Rs). The cDNA for the type I TNF-R, cloned using amino acid sequence data of its soluble form, encodes both the cell surface and a soluble form of the receptor. EMBO Journal 1990; 9: 3269–3278.
 
15.
Aderka D, Engelmann H, Maor Y, Brakebusch C, Wallach D. Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors. J Exp Med. 1992; 75: 323–329.
 
16.
Abe Y, Watanabe Y, Kimura S. The role of tumor necrosis factor receptors in cell signaling and the significance of soluble form levels in the serum. Surg Today. 1994; 24: 197–202.
 
17.
Mazzon E, Esposito E, Di Paola R, Muià C, Crisafulli C, Genovese T, et al. Effect of tumour necrosis factor-alpha receptor 1 genetic deletion on carrageenan-induced acute inflammation: a comparison with etanercept. Clin Exp Immunol. 2008; 153: 136–149.
 
18.
Adamska A, Nikołajuk A, Karczewska-Kupczewska M, Kowalska I, Otziomek E, Górska M, et al. Relationships between serum adiponectin and soluble TNF-α receptors and glucose and lipid oxidation in lean and obese subjects. Acta Diabetol. 2012; 49: 17–24.
 
19.
Kinalski M, Telejko B, Kuźmicki M, Kretowski A, Kinalska I. Tumor necrosis factor alpha system and plasma adiponectin concentration in women with gestational diabetes. Horm Metab Res. 2005; 37: 450–454.
 
20.
Altinova AE, Toruner F, Bozkurt N, Bukan N, Karakoc A, Yetkin I, et al. Circulating concentrations of adiponectin and tumor necrosis factor-alpha in gestational diabetes mellitus. Gynecol Endocrinol. 2007; 23: 161–165.
 
21.
Atègbo JM, Grissa O, Yessoufou A, Hichami A, Dramane KL, Moutairou K, et al. Modulation of adipokines and cytokines in gestational diabetes and macrosomia. J Clin Endocrinol Metab. 2006; 91: 4137–4143.
 
22.
McLachlan KA, O’Neal D, Jenkins A, Alford FP. Do adiponectin, TNFalpha, leptin and CRP relate to insulin resistance in pregnancy? Studies in women with and without gestational diabetes, during and after pregnancy. Diabetes Metab Res Rev. 2006; 22: 131–138.
 
23.
Montazeri S, Nalliah S, Radhakrishnan AK. Is there a genetic variation association in the IL-10 and TNF alpha promoter gene with gestational diabetes mellitus? Hereditas 2010; 147: 94–102.
 
24.
Wang G, Woo CWH, Sung FL, Siow YL, O K, Increased monocyte adhesion to aortic endothelium in rats with hyperhomocyteinaemia: role of chemokine and adhesion molecules. Arterioscler Thromb Vasc Biol. 2002; 22: 1777–1783.
 
25.
Urso C, Hopps E, Caimi G. Adhesion molecules and diabetes mellitus. Clin Ter. 2010; 161: 17–24.
 
26.
Krauss T, Emons G, Kuhn W, Augustin HG, Predictive value of routine circulation soluble endothelial cell adhesion molecule measurements during pregnancy. Clin Chem. 2002; 48: 1418–1425.
 
27.
Matsumoto K, Sera Y, Miyake S, Ueki Y, Serum levels of adhesion molecules correlate with insulin resistance. Atherosclerosis 2002; 161: 243–2444.
 
28.
WHO/NCD/NCS/99.2. WHO consultation: Definition, Diagnosis, and Classification of Diabetes Mellitus and Its Complications Report of a WHO Consultation. Part 1: Diagnosis and Classification of Diabetes Mellitus. World Health Organisation, Geneva 1999.
 
29.
Matthews DR, Hosker JP, Rudensky AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412–419.
 
30.
Matsuda M, DeFronzo R. Insulin sensitivity indices obtained from oral glucose tolerance testing. Diabetes Care 1999; 9: 1462–1470.
 
31.
Dey P, Gupta P, Acharya NK, Rao SN, Ray S, Chakrabarty S, et al. Antioxidants and lipid peroxidation in gestational diabetes – a preliminary study. Indian J Physiol Pharmacol 2008; 52: 149–156.
 
32.
Karacay O, Sepici-Dincel A, Karcaaltincaba D, Sahin D, Yalvaç S, Akyol M, et al. A quantitative evaluation of total antioxidant status and oxidative stress markers in pre-clampsia and gestational diabetic patients in 24–36 weeks of gestation. Diabetes Res Clin Pract. 2010; 89: 231–238.
 
33.
Rajeswari P, Natarajan R, Nadler JL, Kumar D, Kalra VK. Glucose induces lipid peroxidation and inactivation of membrane-associated ion-transport enzymes in human erythrocytes in vivo and in vitro. J Cell Physiol. 1991; 149: 100–109.
 
34.
Ahmed FN, Naqvi FN, Shafiq F. Lipid peroxidation and serum antioxidant enzymes in patients with type 2 diabetes mellitus. Ann N Y Acad Sci. 2006; 1084: 481–489.
 
35.
Lappas M, Permezel M, Rice GE. Release of proinflammatory cytokines and 8-isoprostane from placenta, adipose tissue, and skeletal muscle from normal pregnant women and women with gestational diabetes mellitus. J Clin Endocrinol Metab. 2004; 89: 5627–5633.
 
36.
Omu AE, Al_Azemi MK, Omu FE, Fatinikun T, Abraham S, George S, et al. Butyrylcholinesterase activity in women with diabetes mellitus in pregnancy: correlation with antioxidant activity. J Obstet Gynaecol. 2010; 30: 122–126.
 
37.
Facchini FS, Humphreys MH, DoNascimento CA, Abbasi F, Reaven GM. Relation between insulin resistance and plasma concentrations of lipid hydroperoxides, carotenoids, and tocopherols. Am J Clin Nutr. 2000; 72: 776–779.
 
38.
Kassi E, Dalamaga M, Hroussalas G, Kazanis K, Merantzi G, Zachari A, et al. Adipocyte factors, high-sensitive C-reactive protein levels and lipoxidative stress products in overweight postmenopausal women with normal and impaired OGTT. Maturitas 2010; 67: 72–77.
 
39.
Gupta S, Aziz N, Sekhon L, Agarwal R, Mansour G, Li J, Agarwal A. Lipid peroxidation and antioxidant status in pre-clampsia: a systematic review. Obstet Gynecol Surv. 2009; 64: 750–759.
 
40.
Kinalski M, Kuźmicki M, Telejko B, Bachórzewski R, Buraczyk M, Kretowski A, et al. Tumor necrosis factor-alpha system in patients with gestational diabetes. Przegl Lek. 2006; 63: 173–175.
 
41.
Winkler G, Cseh K, Baranyi E, Melczer Z, Speer G, Hajós P, et al. Tumor necrosis factor system in insulin resistance in gestational diabetes. Diabetes Res Clin Pract. 2002; 56: 93–99.
 
42.
Lappas M, Mitton A, Permezel M. In response to oxidative stress, the expression of inflammatory cytokines and antioxidant enzymes are impaired in placenta, but not adipose tissue, of women with gestational diabetes. J Endocrinol. 2010; 204: 75–84.
 
43.
Coughlan MT, Oliva K, Georgiou HM, Permezel JM, Rice GE. Glucoseinduced release of tumour necrosis factor-alpha from human placental and adipose tissues in gestational diabetes mellitus. Diabet Med. 2001; 18: 921–927.
 
eISSN:1898-2263
ISSN:1232-1966